1,3,5-triazines for treatment of viral diseases

1. A method for treating Human Immuno-Deficiency Virus (HIV) comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound having the formula:

wherein

R 9 and R 10 are members independently selected from H, substituted or unsubstituted alkyl and acyl;

R 3 is H;

R 4 is H;

R 5 is OR 14 , wherein R 14 is a member selected from H and unsubstituted alkyl;

R 6 is OR 14 , wherein R 14 is a member selected from H, substituted or unsubstituted alkyl and P(O)(OR 17 )(OR 17 ), wherein each R 17 is independently selected from H, substituted alkyl, substituted or unsubstituted alkyloxy and substituted or unsubstituted phenyl; and

R 8 is selected from H and unsubstituted alkyl.

2. The method of claim 1 , wherein said compound is given orally.

3. The method of claim 2 , wherein said compound is an enteric formulation.

4. The method of claim 3 , wherein said compound is delivered in an oral osmotic drug delivery device.

5. The method of claim 1 , wherein the HIV is resistant to nucleotide reverse transcriptase inhibitors.

6. The method of claim 1 , comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound having the formula:

7. The method of claim 1 , comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound having the formula:

8. The method of claim 1 , wherein R 6 has the formula:

in which

R 22 is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

Ar is a substituted or unsubstituted aryl.

9. The method of claim 8 , wherein L comprises a moiety that is cleaved in vivo after entry of said compound into a cell.

10. The method of claim 1 , wherein R 6 has the formula:

in which

R 22 is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

n is an integer from 1 to 30.

11. The method of claim 10 , wherein L comprises a moiety that is cleaved in vivo after entry of said compound into a cell.

12. The method of claim 1 , wherein the compound is administered in combination with another antiviral drug.

13. The method of claim 12 , wherein the antiviral drug is a member selected from the group consisting of acyclovir, amantadine azidothymidine (AZT or Zidovudine), ribavirin, amantadine, vidarabine and vidarabine monohydrate (adenine arabinoside, ara-A).

14. The method of claim 1 , wherein the compound has the formula: